Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania
- PMID: 16449481
- DOI: 10.1176/appi.ajp.163.2.272
Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania
Abstract
Objective: Several studies have shown that achieving adequate serum valproate levels is critical to rapid stabilization of acute mania, but estimates of the target therapeutic level have been imprecise. A post hoc analysis of pooled intent-to-treat data from three randomized, placebo-controlled studies of divalproex treatment for acute mania was performed to test a hypothesized linear relationship between serum concentration and response and to determine optimal blood levels for treatment of acute mania.
Method: Subjects (N=374) were stratified into seven groups (six valproate serum level ranges and placebo), and effect size was determined for each. Linearity of dose response was tested with both parametric and nonparametric techniques. ANOVA was used to compare the response at each serum level range with that of placebo as well as the lowest valproate level (< =55.0 microg/ml). The mean serum valproate level was then determined for all subjects with an effect size greater than or equal to the maximal effect derived from linear modeling.
Results: The fit of blood level and response to a linear model was good. Efficacy was significantly greater than placebo beginning at the 71.4-85.0 microg/ml range and for all higher valproate levels; the 94.1-107.0 and >107.0 microg/ml groups were superior to the lowest valproate serum level group. The effect size associated with highest serum levels (>94 microg/ml) was 1.06 (0.59 after placebo correction). Subjects obtaining this effect or greater (N=84) had a mean serum level of 87.5 microg/ml. Blood levels in the lowest effective range were 60% more effective than placebo and in the higher ranges were 120% more effective. Tolerability appeared similar for all groups.
Conclusions: The results of this study suggest that there is a linear relationship between valproate serum concentration and response and that the target blood level of valproate for best response in acute mania is above 94 microg/ml.
Similar articles
-
A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania.J Clin Psychiatry. 2010 Apr;71(4):426-32. doi: 10.4088/JCP.08m04960yel. Epub 2010 Mar 9. J Clin Psychiatry. 2010. PMID: 20361904 Clinical Trial.
-
Relation of serum valproate concentration to response in mania.Am J Psychiatry. 1996 Jun;153(6):765-70. doi: 10.1176/ajp.153.6.765. Am J Psychiatry. 1996. PMID: 8633687 Clinical Trial.
-
Quetiapine in the treatment of acute mania: target dose for efficacious treatment.J Affect Disord. 2007;100 Suppl 1:S23-31. doi: 10.1016/j.jad.2007.02.009. Epub 2007 Mar 26. J Affect Disord. 2007. PMID: 17382403
-
Divalproex in the treatment of bipolar disorder.Psychopharmacol Bull. 2003;37 Suppl 2:67-73. Psychopharmacol Bull. 2003. PMID: 15021862 Review.
-
Spectrum of effectiveness of valproate in neuropsychiatry.Expert Rev Neurother. 2007 Jan;7(1):9-16. doi: 10.1586/14737175.7.1.9. Expert Rev Neurother. 2007. PMID: 17187491 Review.
Cited by
-
A 5-Year Study of Lithium and Valproic Acid Drug Monitoring in Patients with Bipolar Disorders in an Italian Clinical Center.Pharmaceuticals (Basel). 2022 Jan 17;15(1):105. doi: 10.3390/ph15010105. Pharmaceuticals (Basel). 2022. PMID: 35056162 Free PMC article.
-
Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder.Eur J Clin Pharmacol. 2022 Mar;78(3):405-418. doi: 10.1007/s00228-021-03246-2. Epub 2021 Dec 2. Eur J Clin Pharmacol. 2022. PMID: 34854947
-
Is Valproate Depressogenic in Patients Remitting from Acute Mania? Case Series.Case Rep Psychiatry. 2015;2015:456830. doi: 10.1155/2015/456830. Epub 2015 Nov 17. Case Rep Psychiatry. 2015. PMID: 26664794 Free PMC article.
-
Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.Neuropsychopharmacology. 2010 Mar;35(4):990-8. doi: 10.1038/npp.2009.202. Epub 2009 Dec 9. Neuropsychopharmacology. 2010. PMID: 20010551 Free PMC article. Clinical Trial.
-
Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update.Front Pharmacol. 2022 Sep 15;13:926607. doi: 10.3389/fphar.2022.926607. eCollection 2022. Front Pharmacol. 2022. PMID: 36188551 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical